Global Drug Modeling Softwares 麻豆原创 Research Report 2024

Publication ID:

PB506242215

Publication Date:

June 11, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

IT Services [2]

Computing & Electronics [3]

Description:

Drug Modeling has become an essential tool in the drug design process. Software based drug discovery and development methods are playing key a role in the development of novel drugs. Software based methods such as molecular modeling, structure-based drug design, structure-based virtual screening, ligand interaction and molecular dynamics are considered to be powerful tool for the investigation of pharmacokinetic and pharmacodynamic properties of drugs. These methods are fast, accurate, and provide valuable insights of experimental findings and mechanisms of action. Additionally, appropriate implementation of these techniques may help in reducing drug designing and development cost.
The global Drug Modeling Softwares market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Drug Modeling Softwares, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drug Modeling Softwares.
Report Scope
The Drug Modeling Softwares market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Drug Modeling Softwares market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drug Modeling Softwares companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
JSR Corporation(Crown Bioscience)
Chemical Computing Group ULC
Nimbus Therapeutics
Schrodinger, Inc
Genedata AG
Biognos AB
Compugen Ltd
Dassault Systemes
Acellera
Instem(Leadscope)
Segment by Type
Database
Software
Others
Segment by Application
Drug Discovery and Development
Computational Physiological Medicine
Disease Modelling
Medical Imaging
Predictive Analysis of Drug Targets
Simulation Software
Cellular Simulation
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drug Modeling Softwares companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Drug Modeling Softwares 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Database
1.2.3 Software
1.2.4 Others
1.3 麻豆原创 by Application
1.3.1 Global Drug Modeling Softwares 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Drug Discovery and Development
1.3.3 Computational Physiological Medicine
1.3.4 Disease Modelling
1.3.5 Medical Imaging
1.3.6 Predictive Analysis of Drug Targets
1.3.7 Simulation Software
1.3.8 Cellular Simulation
1.3.9 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Drug Modeling Softwares 麻豆原创 Perspective (2019-2030)
2.2 Drug Modeling Softwares Growth Trends by Region
2.2.1 Global Drug Modeling Softwares 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Drug Modeling Softwares Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Drug Modeling Softwares Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Drug Modeling Softwares 麻豆原创 Dynamics
2.3.1 Drug Modeling Softwares Industry Trends
2.3.2 Drug Modeling Softwares 麻豆原创 Drivers
2.3.3 Drug Modeling Softwares 麻豆原创 Challenges
2.3.4 Drug Modeling Softwares 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drug Modeling Softwares Players by Revenue
3.1.1 Global Top Drug Modeling Softwares Players by Revenue (2019-2024)
3.1.2 Global Drug Modeling Softwares Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Drug Modeling Softwares 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Drug Modeling Softwares Revenue
3.4 Global Drug Modeling Softwares 麻豆原创 Concentration Ratio
3.4.1 Global Drug Modeling Softwares 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drug Modeling Softwares Revenue in 2023
3.5 Drug Modeling Softwares Key Players Head office and Area Served
3.6 Key Players Drug Modeling Softwares Product Solution and Service
3.7 Date of Enter into Drug Modeling Softwares 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Drug Modeling Softwares Breakdown Data by Type
4.1 Global Drug Modeling Softwares Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Drug Modeling Softwares Forecasted 麻豆原创 Size by Type (2025-2030)
5 Drug Modeling Softwares Breakdown Data by Application
5.1 Global Drug Modeling Softwares Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Drug Modeling Softwares Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Drug Modeling Softwares 麻豆原创 Size (2019-2030)
6.2 North America Drug Modeling Softwares 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Drug Modeling Softwares 麻豆原创 Size by Country (2019-2024)
6.4 North America Drug Modeling Softwares 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Drug Modeling Softwares 麻豆原创 Size (2019-2030)
7.2 Europe Drug Modeling Softwares 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Drug Modeling Softwares 麻豆原创 Size by Country (2019-2024)
7.4 Europe Drug Modeling Softwares 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Drug Modeling Softwares 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Drug Modeling Softwares 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Drug Modeling Softwares 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Drug Modeling Softwares 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Drug Modeling Softwares 麻豆原创 Size (2019-2030)
9.2 Latin America Drug Modeling Softwares 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Drug Modeling Softwares 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Drug Modeling Softwares 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drug Modeling Softwares 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Drug Modeling Softwares 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Drug Modeling Softwares 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Drug Modeling Softwares 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 JSR Corporation(Crown Bioscience)
11.1.1 JSR Corporation(Crown Bioscience) Company Detail
11.1.2 JSR Corporation(Crown Bioscience) Business Overview
11.1.3 JSR Corporation(Crown Bioscience) Drug Modeling Softwares Introduction
11.1.4 JSR Corporation(Crown Bioscience) Revenue in Drug Modeling Softwares Business (2019-2024)
11.1.5 JSR Corporation(Crown Bioscience) Recent Development
11.2 Chemical Computing Group ULC
11.2.1 Chemical Computing Group ULC Company Detail
11.2.2 Chemical Computing Group ULC Business Overview
11.2.3 Chemical Computing Group ULC Drug Modeling Softwares Introduction
11.2.4 Chemical Computing Group ULC Revenue in Drug Modeling Softwares Business (2019-2024)
11.2.5 Chemical Computing Group ULC Recent Development
11.3 Nimbus Therapeutics
11.3.1 Nimbus Therapeutics Company Detail
11.3.2 Nimbus Therapeutics Business Overview
11.3.3 Nimbus Therapeutics Drug Modeling Softwares Introduction
11.3.4 Nimbus Therapeutics Revenue in Drug Modeling Softwares Business (2019-2024)
11.3.5 Nimbus Therapeutics Recent Development
11.4 Schrodinger, Inc
11.4.1 Schrodinger, Inc Company Detail
11.4.2 Schrodinger, Inc Business Overview
11.4.3 Schrodinger, Inc Drug Modeling Softwares Introduction
11.4.4 Schrodinger, Inc Revenue in Drug Modeling Softwares Business (2019-2024)
11.4.5 Schrodinger, Inc Recent Development
11.5 Genedata AG
11.5.1 Genedata AG Company Detail
11.5.2 Genedata AG Business Overview
11.5.3 Genedata AG Drug Modeling Softwares Introduction
11.5.4 Genedata AG Revenue in Drug Modeling Softwares Business (2019-2024)
11.5.5 Genedata AG Recent Development
11.6 Biognos AB
11.6.1 Biognos AB Company Detail
11.6.2 Biognos AB Business Overview
11.6.3 Biognos AB Drug Modeling Softwares Introduction
11.6.4 Biognos AB Revenue in Drug Modeling Softwares Business (2019-2024)
11.6.5 Biognos AB Recent Development
11.7 Compugen Ltd
11.7.1 Compugen Ltd Company Detail
11.7.2 Compugen Ltd Business Overview
11.7.3 Compugen Ltd Drug Modeling Softwares Introduction
11.7.4 Compugen Ltd Revenue in Drug Modeling Softwares Business (2019-2024)
11.7.5 Compugen Ltd Recent Development
11.8 Dassault Systemes
11.8.1 Dassault Systemes Company Detail
11.8.2 Dassault Systemes Business Overview
11.8.3 Dassault Systemes Drug Modeling Softwares Introduction
11.8.4 Dassault Systemes Revenue in Drug Modeling Softwares Business (2019-2024)
11.8.5 Dassault Systemes Recent Development
11.9 Acellera
11.9.1 Acellera Company Detail
11.9.2 Acellera Business Overview
11.9.3 Acellera Drug Modeling Softwares Introduction
11.9.4 Acellera Revenue in Drug Modeling Softwares Business (2019-2024)
11.9.5 Acellera Recent Development
11.10 Instem(Leadscope)
11.10.1 Instem(Leadscope) Company Detail
11.10.2 Instem(Leadscope) Business Overview
11.10.3 Instem(Leadscope) Drug Modeling Softwares Introduction
11.10.4 Instem(Leadscope) Revenue in Drug Modeling Softwares Business (2019-2024)
11.10.5 Instem(Leadscope) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

JSR Corporation(Crown Bioscience)
Chemical Computing Group ULC
Nimbus Therapeutics
Schrodinger, Inc
Genedata AG
Biognos AB
Compugen Ltd
Dassault Systemes
Acellera
Instem(Leadscope)

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.